secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001743881-25-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q3 2025: $120.7M revenue, Attruby launch accelerating; positive Phase 3 data for BBP-418 and encaleret
--------------------------------------------------------------------------------

- Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.
- Net loss $182.7M ($0.95/sh) vs $162.0M ($0.86/sh) in prior year; cash $645.9M.
- Attruby: 5,259 prescriptions written by 1,355 prescribers since Nov 2024 approval.
- BBP-418 Phase 3 met endpoints: glycosylated αDG increased 1.8x (p<0.0001); NDA filing planned 1H 2026.
- Encaleret Phase 3 met primary endpoint: 76% achieved target calcium vs 4% on conventional (p<0.0001); NDA in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/0001743881-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001743881-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer